Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyronaridine-Artesunate Dose-Escalation in Children with Malaria
NCT00331136Phase 2Completed
- Sponsor
- Medicines for Malaria Venture
- Start
- Jun 2006
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pyronaridine in Plasmodium falciparum malaria (4 arms), sponsored by Medicines for Malaria Venture. Primary endpoint: Percentage of Patients With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28. Started Jun 2006; status: completed.
02
Drugs
pyronaridine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT00331136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00331136.